Literature DB >> 7817380

HLA class I self peptides isolated from a T-cell leukemia reveal the allele-specific motif of HLA-B38.

A I Colovai1, N Suciu-Foca, G E Baiulescu, P E Harris.   

Abstract

Naturally-processed self peptides bound to HLA class I molecules of a T-cell leukemia (HLA-A1, A31, B38, B58) were isolated for sequence analysis. Acid-eluted peptides were subjected to reversed-phase HPLC separation and single-fraction sequencing was performed by Edman degradation. The peptides were found to be mostly nonamers and could be grouped into three distinct structural motifs. One of the peptide groups consistently displayed histidine at position 2 and a bulky hydrophobic residue at the C-terminus (XHXPXXXXY/F). The only HLA class I structure expressed by this T-cell leukemia which is consistent with the binding of peptides carrying this sequence motif is HLA-B38. A peptide binding assay confirmed this assignment. HLA-B38 is present in 10-12% of the Jewish population and is associated with several autoimmune disorders. The HLA-B38 motif may be an important tool for identifying potential T-cell epitopes involved in these diseases and for designing peptide vaccines.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7817380     DOI: 10.1111/j.1399-0039.1994.tb02361.x

Source DB:  PubMed          Journal:  Tissue Antigens        ISSN: 0001-2815


  2 in total

1.  A multi-factorial genetic model for prognostic assessment of high risk melanoma patients receiving adjuvant interferon.

Authors:  Ena Wang; Yingdong Zhao; Alessandro Monaco; Lorenzo Uccellini; John M Kirkwood; Maria Spyropoulou-Vlachou; Monica C Panelli; Francesco M Marincola; Helen Gogas
Journal:  PLoS One       Date:  2012-07-24       Impact factor: 3.240

2.  Analysis of naturally processed human histocompatibility leukocyte antigen class I-bound peptides from hepatocellular carcinoma tissues in vivo.

Authors:  H Kobayashi; K Sato; N Miyokawa; S Kimura; M Nakashima; M Katagiri
Journal:  Jpn J Cancer Res       Date:  1995-10
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.